Iberdomide Capsules 0.75 mg, 1 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 0.75 mg, 1 mg

Reference Brands: Zenbexus (Bristol Myers Squibb)

Category: Oncology Cancer Care

Iberdomide (Zenbexus, Bristol Myers Squibb) is an oral CELMoD for multiple myeloma, used with daratumumab and dexamethasone. The US FDA approved it in August 2026. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Product Description:

Iberdomide is a cereblon E3 ligase modulator (CELMoD), a successor to lenalidomide and pomalidomide. It binds cereblon much more strongly and causes faster, deeper breakdown of Ikaros and Aiolos, two proteins myeloma cells depend on. It also stimulates the immune system against the tumour, and it can work in myeloma that has become resistant to the older drugs.

The US FDA granted iberdomide accelerated approval as Zenbexus in August 2026 for adults with multiple myeloma who have had at least one prior line of therapy, in combination with subcutaneous daratumumab and dexamethasone. It is supplied as 0.75 mg and 1 mg capsules. Like other drugs in its family it can harm an unborn baby, so pregnancy prevention is required.

Sourcing and licensing notes. Iberdomide is patented and made only by Bristol Myers Squibb; there is no generic. Generic lenalidomide and pomalidomide are widely available, and we supply those too. We handle enquiries for authorised supply of Zenbexus and connect developers and licensees interested in the molecule ahead of patent expiry.